Immunic (IMUX) News Today $0.84 +0.04 (+4.51%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$0.85 +0.01 (+1.75%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Immunic (NASDAQ:IMUX) Raised to Strong-Buy at LADENBURG THALM/SH SHOctober 18 at 7:34 AM | marketbeat.comAberdeen Group plc Buys 7,184,457 Shares of Immunic, Inc. $IMUXOctober 17, 2025 | marketbeat.comImmunic initiated with a Buy at LadenburgOctober 16, 2025 | msn.comImmunic targeting mental and physical challenges facing MS patients - ICYMIOctober 11, 2025 | proactiveinvestors.comImmunic (NASDAQ:IMUX) Earns Sell (D-) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comWilliam Blair Remains a Buy on Immunic (IMUX)October 2, 2025 | theglobeandmail.comPositive Signs As Multiple Insiders Buy Immunic StockOctober 2, 2025 | finance.yahoo.comImmunic Advances Phase 3 Trials and Financial HealthOctober 2, 2025 | theglobeandmail.comChardan Capital Estimates Immunic FY2026 EarningsOctober 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Investor Conferences in OctoberOctober 1, 2025 | prnewswire.comBrokers Issue Forecasts for Immunic FY2025 EarningsOctober 1, 2025 | marketbeat.comChardan Capital Initiates Coverage of Immunic (IMUX) with Buy RecommendationSeptember 29, 2025 | msn.comImmunic is aiming for a big breakthrough in the treatment of multiple sclerosisSeptember 29, 2025 | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesSeptember 29, 2025 | marketbeat.comChardan Capital Initiates Coverage on Immunic (NASDAQ:IMUX)September 29, 2025 | marketbeat.comHC Wainwright & Co. Reiterates Immunic (IMUX) Buy RecommendationSeptember 26, 2025 | msn.comImmunic (NASDAQ:IMUX) Earns "Buy" Rating from HC WainwrightSeptember 26, 2025 | marketbeat.comD. Boral Capital Maintains Immunic (IMUX) Buy RecommendationSeptember 26, 2025 | msn.comImmunic Presents Promising Phase 2 Trial ResultsSeptember 25, 2025 | msn.comImmunic's (IMUX) Buy Rating Reaffirmed at D. Boral CapitalSeptember 25, 2025 | marketbeat.comImmunic highlights multiple sclerosis drug findings at key neurology gatheringSeptember 25, 2025 | proactiveinvestors.comImmunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple SclerosisSeptember 25, 2025 | prnewswire.comFocus Partners Wealth Has $2.82 Million Holdings in Immunic, Inc. $IMUXSeptember 17, 2025 | marketbeat.comImmunic receives notice of allowance for vidofludimus calcium patentSeptember 9, 2025 | msn.comImmunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MSSeptember 9, 2025 | proactiveinvestors.comImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisSeptember 9, 2025 | prnewswire.comB. Riley Weighs in on Immunic's Q3 Earnings (NASDAQ:IMUX)September 6, 2025 | marketbeat.comImmunic to Participate in Investor and Scientific Conferences in SeptemberSeptember 4, 2025 | prnewswire.comCan Immunic (NASDAQ:IMUX) Afford To Invest In Growth?September 1, 2025 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from BrokeragesAugust 27, 2025 | marketbeat.com1,059,484 Shares in Immunic, Inc. $IMUX Acquired by Aberdeen Group plcAugust 24, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for ImmunicAugust 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for Immunic Q1 Earnings?August 12, 2025 | marketbeat.comWilliam Blair Predicts Immunic's Q1 Earnings (NASDAQ:IMUX)August 12, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Announces Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comImmunic, Inc. (IMUX) latest stock news and headlines – Yahoo FinanceAugust 10, 2025 | sg.finance.yahoo.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)August 9, 2025 | marketbeat.comImmunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIAugust 9, 2025 | proactiveinvestors.comImmunic (IMUX) Q2 Loss Widens 25%August 8, 2025 | theglobeandmail.comImmunic advances MS drug program with Phase 3 trials fully enrolledAugust 7, 2025 | proactiveinvestors.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ...August 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 31, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Stock Price Down 3.6% - Time to Sell?July 29, 2025 | marketbeat.comImmunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS TrialJuly 25, 2025 | msn.comImmunic board authorizes up to 35 million stock ... - Investing.comJuly 13, 2025 | investing.comImmunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo FinanceJuly 9, 2025 | ca.finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by BrokeragesJuly 6, 2025 | marketbeat.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.920.50▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼44▲IMUX Articles Average Week Get the Latest News and Ratings for IMUX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immunic and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AC Immune News Contineum Therapeutics News Annexon News Canopy Growth News Galectin Therapeutics News Lyell Immunopharma News Tenaya Therapeutics News Editas Medicine News Aardvark Therapeutics News Mereo BioPharma Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts